Loading…
← Back to schedule
Comparative Outcomes of Post-Transplant Cyclophosphamide (PTCy) vs Non-PTCy-Based GVHD Prophylaxis Regimens in Allogeneic Hematopoietic Stem Cell Transplantation
Friday April 25, 2025 9:10am - 9:25am EDT
Athena J
Title: Comparative Outcomes of Post-Transplant Cyclophosphamide (PTCy) vs Non-PTCy-Based GVHD Prophylaxis Regimens in Allogeneic Hematopoietic Stem Cell Transplantation


Authors: Gyunash Akibova, Kristen Kilby, Henry Kent Holland, Justin LaPorte, Eva Karam 
 
Objective: This study aims to evaluate the long-term outcomes of PTCy-based GVHD prophylaxis in alloHSCT recipients over a 10-year period at Northside Hospital. The primary objective is to assess chronic GVHD-free relapse-free survival (CGFRFS) in patients receiving PTCy compared to those who did not. Secondary objectives include evaluating overall survival (OS), relapse-free survival (RFS), NRM, and the incidence of acute and chronic GVHD.
 
Background: Graft-versus-host disease (GVHD) is a significant complication following allogeneic hematopoietic stem cell transplantation (alloHSCT), particularly in patients with human leukocyte antigen (HLA)-mismatched or haploidentical donors. Traditional GVHD prophylaxis regimens, such as a calcineurin inhibitor (CI) and methotrexate (MTX), have been effective but are still associated with risks of acute and chronic GVHD, as well as non-relapse mortality (NRM). Post-transplant cyclophosphamide (PTCy) alone or in combination with a CI with or without mycophenolate has emerged as a promising approach for GVHD prophylaxis, showing favorable results in reducing GVHD incidence in alloHSCT recipients. A recent retrospective study at The Blood and Marrow Transplant Program at Northside Hospital suggested the benefits of PTCy beyond haploidentical transplants, prompting further investigation into its long-term outcomes.
 
Methods: This single-center, retrospective chart review will include patients who underwent alloHSCT at Northside Hospital between January 1, 2013, and December 31, 2023. Recipient health records will be identified using a proprietary database to identify patients who received an alloHSCT during the study period. Data will be extracted from electronic health records (Cerner Powerchart®, OncoEMR®) and hospital databases. Patients will be excluded if they are receiving a second alloHSCT. Key data points include patient demographics, HLA disparity, use of PTCy, GVHD incidence, time to GVHD onset, disease relapse, and survival outcomes. 
 
Results: In Progress
 
Conclusion: In Progress
Presenters
avatar for Gyunash Akibova

Gyunash Akibova

PGY2 Pharmacy Oncology Resident, Northside Hospital
PGY2 Pharmacy Oncology Resident at Northside Hospital Atlanta 
Evaluators
avatar for Azur Eckley

Azur Eckley

Clinical Pharmacy Practitioner, Ralph H. Johnson VA Medical Center
Dr. Azur Eckley, BCPS  is currently a Clinical Pharmacy Practitioner in ambulatory care specialty clinics including cardiology, gastroenterology and nephrology at the Ralph H Johnson VA Medical Center in Charleston, SC. She is a graduate of the University of Tennessee College of... Read More →
BS
Friday April 25, 2025 9:10am - 9:25am EDT
Athena J
  Transplant (TRP), Northside Hospital
  • global Y
Feedback form is now closed.

Attendees (9)


Sign up or log in to save this to your schedule, view media, check-in, leave feedback and see who's attending!

Tweet Share
Share Modal

Share this link via

Or copy link